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incurred greater costs for hospitalization (additional $7767 for
CD-related, $9417 for all-cause; both p = 0.001), outpatient
visits (additional $1025 for CD-related, p < 0.001; $1307 for
all-cause, p = 0.003), and total medical services (additional
$5236 for CD-related and $6953 for all-cause, both p < 0.001).
CONCLUSION: More than one-third of the CD patients on
inﬂiximab maintenance therapy in the cohort were non-adherent
to therapy within 1 year. Non-adherence was associated with
greater medical service utilization and costs.
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OBJECTIVE: The Inﬂammatory Bowel Disease Questionnaire
(IBDQ) is a valid, reliable, and sensitive measure to assess
patients’ subjective health status and quality of life (QOL). Prior
to its use in an international clinical trial of active Ulcerative
Colitis, the 32-item IBDQ underwent linguistic validation in 35
languages or cultures, including 8 Indian languages. METHODS:
For languages with no prior translation, the Canadian English
original was translated by specialists in each target country fol-
lowing a standardized methodology: 1) two independent forward
translations were done by professional translators, native speak-
ers of the target language and ﬂuent in English; 2) comparison
with the original and reconciliation of translations by the target
country specialist were made; 3) backward translation was per-
formed by a native English speaker; 4) comparison of source and
backtranslations were reviewed with the IBDQ developer; 5)
comprehension testing of 5 patients with moderately to severely
active Ulcerative Colitis was performed. Pre-existing translations
were integrated into the process as appropriate. RESULTS: Lin-
guistic and conceptual challenges emerged in translating the
7-point Likert scale response choices (RC). Literal translation of
the original 7-point RCs was not suitable in all languages.
Anchors were chosen to be comparable to the original; the ﬁve
middle response choices were logical and equidistant from one
another. Some wording adaptation was needed for most coun-
tries to reﬂect local idiomatic expressions; particularly, “bowel
movements” required more precise translation in most lan-
guages. CONCLUSION: The 35 language versions of the IBDQ
were established using a rigorous process to ensure conceptual
harmonization that would permit international comparisons and
data pooling. The IBDQ may now be used conﬁdently in these
countries to evaluate the impact of inﬂammatory bowel disease
on patients’ daily lives.
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OBJECTIVE: Diarrhea without infectious etiology (episodic,
chronic) is reported in excess of 20% of HIV/AIDS patients
receiving standard of care HAART therapy. Diarrhea of any
severity and/or frequency negatively affects health-related quality
of life (HRQoL) for these individuals. No instrument speciﬁc to
the impact of HIV/AIDS-related diarrhea currently exists. To
measure a HRQoL beneﬁt from a new oral antidiarrheal in
clinical testing, a new PRO instrument is being developed.
METHODS: Comprehensive review of the HRQoL literature of
diarrhea in the general and HIV/AIDS populations was con-
ducted and experts in HIV and GI medicine were interviewed.
Focus groups of HIV+ individuals experiencing diarrhea were
undertaken. The psychometric properties of the draft question-
naire items were evaluated from data collected via the Internet in
320 respondents. Also collected within the cross-sectional, devel-
opment study were respondent demographics, bowel movement
history, SF-12, and Work Productivity & Activity Impairment
(WPAI) questionnaire. Following item reduction, content validity
was evaluated by cognitive debrieﬁng. RESULTS: Literature
review, expert feedback, and focus groups informed the concep-
tual model and construction of 41 draft questions regarding
HRQoL related to chronic diarrhea among HIV+ individuals.
Item reduction was achieved by exploratory and conﬁrmatory
factor analyses and conﬁrmed a one-factor best ﬁt model. A
generalized, partial credit IRT analysis facilitated further item
reduction. Differential item functioning analyses conﬁrmed no
signiﬁcant differences in item performance among subgroups
tested. Convergent and discriminate validity were supported by
correlations with SF-12 scales, WPAI and self-reported symptom
frequency and severity scores (correlation coefﬁcients 0.58 to
0.71), and analysis of variance among clinically deﬁned diarrhea
severity (F = 32, p < 0.0001, ç2 0.17). CONCLUSION: A newly
developed survey assessing the impact of chronic diarrhea on
HIV+ patients has demonstrated acceptable psychometric prop-
erties. The survey will be validated in a double-blind, placebo-
controlled diarrhea treatment study.
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OBJECTIVE: To describe gastroesophageal reﬂux disease
(GERD) patients who are partial responders to treatment of
proton pump inhibitors (PPI) in terms of their health care utili-
zation, quality of life and work productivity. METHODS: The
analysis is based on the National Health and Wellness Survey
(NHWS) conducted by the Consumer Health Sciences (CHS) in
USA 2006. Partial responders are deﬁned as diagnosed GERD
patients with remaining at least moderate symptoms 4 times/
week or more after two months PPI-treatment (n = 1433). This
group is compared to 1) GERD patients with only mild symp-
toms or moderate to severe symptoms less than 4 times/week
after a short course of PPI treatment (n = 281), and 2) all indi-
viduals, excluding partial responders, who self-reported GERD,
(n = 19,817). RESULTS: Partial responders use PPI on average
24.5 days/month which is 7.4 days more than patients respond-
ing well and 1.2 days more than all GERD patients. The SF-8
physical summary score is 38.6 for partial responders, which is
5.3 points less than for patients responding well and 7.4 points
less than for all GERD patients. The mental summary score for
partial responders is 41.9 which is 4.3 and 4.6 points less for
patients responding well and all GERD patients, respectively.
Partial responders lost 10.9 hours per week due to reduced
productivity at work, which is 2.4 hours more than for patients
responding well and 3.8 hours more than for all GERD patients.
Partial responders consume resources and impose total produc-
tivity losses equivalent to $2603 per month, which is $724 more
than for patients responding well and $1162 more than for
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all GERD patients. CONCLUSION: Partial responders to PPI
treatment are more costly and score lower on physical and
mental dimensions of HRQoL than patients responding well to
PPI treatment and GERD patients in general.
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OBJECTIVES: This study aims to examine whether the test-
retest reliability of SF-36, WHOQOL-BREF, and EQ-5D
questionnaires will be changed by different administration
approaches by which patients with chronic liver disease self-
report their quality of life. METHODS: Patients with chronic
liver disease were recruited from the outpatient department of a
medical centre in Taiwan. Their self-reported questionnaires
were collected by two approaches. The ﬁrst approach patients
received was an interview and questionnaire in hospital. They
returned the retest questionnaire by mail two weeks later. In the
second approach, patients were instructed to ﬁll out both test and
retest questionnaires at home and send back by two separate
mails. The time gap was also two weeks. After scoring question-
naires, a paired-t test was conducted to compare test-retest
reliability for three questionnaires. The mean score difference
between two approaches was examined by independent t test.
An analyses of mean score differences of different domains
were performed by multiple linear regressions. RESULTS: Of 69
patients recruited for the ﬁrst approach; 52 persons completed
both questionnaires (75%), while the response rate of the second
approach was 84% (127 of 151). The results indicate that there
is no statistically signiﬁcant difference in the test-retest reliability
of SF-36, WHOQOL-BREF, and EQ-5D questionnaires. There
was also no signiﬁcant difference in the test-retest results between
two approaches, except in the dimension ‘pain/discomfort’ mean
difference (0.3  1.2 and -0.1  1.1, p = 0.03) by EQ-5D.
Similar results (p = 0.04) were also found by multiple linear
regression, after controlling age, sex, and education. This reﬂects
that greater pain/discomfort was more likely to present in the
ﬁrst approach as compared to that in the second one. CONCLU-
SIONS: Alternative administration approaches did affect the
results of test-retest questionnaires, which idicated that the
Hawthorne Effect occurred in the interview in hospital.
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OBJECTIVE: Current GERD assessment questionnaires for
adults are limited in their ability to capture nocturnal symptoms.
The objective of this study was to develop and validate an instru-
ment to assess severity and impact of nocturnal GERD symp-
toms. METHODS: Two focus groups and 16 cognitive debrieﬁng
interviews were conducted among patients with GERD to iden-
tify key issues and concerns related to nocturnal GERD symp-
toms. The resulting 29-item draft instrument was included in a
study of 196 patients diagnosed with GERD at 12 clinics in the
United States to evaluate the psychometric properties. Assess-
ments were conducted at baseline and at 4 weeks. Construct
validity was evaluated using the Patient Assessment of Upper
Gastrointestinal Disorders Symptoms Questionnaire (PAGI-
SYM), Patient Assessment of Upper Gastrointestinal Disorders-
Quality of Life (PAGI-QOL), number of nights with symptoms,
disability days, and clinician and patient assessment of GERD
severity. Exploratory factor analyses and item response theory
analyses were conducted to ﬁnalize items and subscales.
RESULTS: Mean age of participants was 45 years; 76% were
female and 68% were Caucasian. Patient-rated severity at base-
line was mild or moderate for 69% of participants, with 48%
reporting GERD-related symptoms 2–3 nights within the past
week. The ﬁnal questionnaire includes 20 items and consists of 3
subscales: nocturnal symptoms; morning impact; and concern
regarding nocturnal GERD. The subscales demonstrated internal
consistency reliability (Cronbach’s alpha 0.92–0.95). The sub-
scale scores were statistically signiﬁcantly correlated with sub-
scales of the PAGI-SYM and PAGI-QOL (0.41–0.81; all
p < 0.0001), number of nights with GERD symptoms (0.45–
0.54; all p < 0.0001), disability days (0.19–0.43; all p < 0.05),
and clinician and patient-reported disease severity (0.46–0.72; all
p < 0.0001). CONCLUSION: Results support the reliability and
validity of the newly developed questionnaire as a measure of
severity of nocturnal GERD symptoms, morning impact, and
concern related to nocturnal GERD.
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OBJECTIVE: To determine the prevalence and severity of
constipation among persons receiving hospice care in the
United States, using longitudinal patient-reported outcomes.
METHODS: Data was obtained from excelleRx, Inc, a national
hospice pharmacy. Patient-reported symptom outcome data were
collected by telephone for each patient by trained research assis-
tants within the ﬁrst three days of hospice admission. Data
collection continued every three to four days until patients were
discharged, or unable or unwilling to report data or dead.
Patients rated constipation on a four-point verbal rating scale of
none, mild, moderate, and severe. The sample for our analysis
came from ﬁve participating hospices and included all discharged
or deceased patients receiving home hospice care with an admis-
sion assessment record and at least one subsequent telephone
assessment for constipation between April 1, 2006 and October
20, 2007. The ﬁrst patient reported constipation assessment
score post hospice admission was used to estimate prevalence
and severity of constipation. RESULTS: A total of 309 patients
met the inclusion criteria, the majority of which were female
(n = 167, 54%), Caucasian (n = 282, 91%), >65 years of age
(n = 238, 77%) and had a primary diagnosis of cancer (n = 223,
72%). All patients were prescribed opioid therapy during their
hospice experience. Constipation was reported at the ﬁrst assess-
ment post admission by 26% of the patients (n = 80), 28.7 % of
patients with cancer (n = 64) and 18.6% of patients without
cancer (n = 16). Most patients who reported constipation were
female (58.8%) and >65 years (78.8%). Constipation intensity
was rated as mild (n = 32; 40%), moderate (n = 23; 28.8%)
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